secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eiger BioPharmaceuticals, Inc. (—)
CIK:        0001305253
Form:       8-K
Filed at:   2023-06-30T23:59:59+00:00
Accession:  0001193125-23-180435
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eiger appoints David Apelian as permanent CEO; grants 750,000 stock options
---------------------------------------------------------------------------

- David Apelian, Interim CEO since Dec 2022, named CEO effective June 28, 2023; remains on Board.
- Annual salary of $650,000 with bonus target of 60% of base salary.
- Grant of nonstatutory stock options for 750,000 shares vesting monthly over 48 months.
- Severance includes 12 months salary plus prorated target bonus on termination without cause or for good reason.
- Change-in-control severance: 18 months salary, full equity acceleration, COBRA coverage up to 18 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1305253/000119312523180435/0001193125-23-180435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1305253/000119312523180435/d503710d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-180435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer